A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

Inclusion Criteria:

• Confirmed diagnosis of Type 3 von Willebrand disease (VWD), based on medical records

• Preexisting medical record verifying the status of von Willebrand factor (VWF)inhibitor (positive or negative, including titer if available)

• Adequate hematologic, hepatic, and renal function

• For participants of childbearing potential: agreement to remain abstinent or adhereto the contraception requirements

Additional Inclusion Criteria for Arms A and B:

• Documented previous use of on-demand therapy with intermittent (less than once aweek) on-demand SOC therapy for VWD

• Having ≥2 treated bleeds (except menstrual bleeds) with factor concentrate within 24weeks prior to enrollment

Additional Inclusion Criteria for Arm C:

• Documented and confirmed previous use of SOC prophylactic therapy for VWD (1-3 timesweekly, as per prescribed dose) as described in the eligibility of Study WP45335

• Have completed all study requirements as defined in the WP45335 protocol for atleast 24 weeks

Exclusion Criteria:

• Inherited or acquired bleeding disorder other than Congenital Type 3 VWD

• History of gastrointestinal bleeding within 18 months prior to enrollment, or anyprevious diagnosis of angiodysplasia

• History of intracranial hemorrhage

• Previous or current treatment for thromboembolic disease or signs of thromboembolicdisease

• Other conditions (e.g., certain autoimmune diseases) that may increase risk ofbleeding or thrombosis

• History of clinically significant hypersensitivity associated with monoclonalantibody therapies or components of the emicizumab injection

• Use of systemic immunomodulators (e.g., interferon) at enrollment or planned useduring the study, with the exception of anti-retroviral therapy